Impact of febrile neutropenia and colony stimulating factor use on chemotherapy delivery in patients with lymphoma: Results from the INC-EU prospective observational European neutropenia study.

被引：0
|
作者：
Pettengell, Ruth
Bosly, Andre
Szucs, Thomas D.
Jackisch, Christian
Leonard, Robert
Paridaens, Robert
Constenla, Manuel
Schwenkglenks, Matthias
机构：
来源：
BLOOD | 2006年 / 108卷 / 11期
关键词：
D O I：
10.1182/blood.V108.11.2444.2444
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2444
引用
收藏
页码：692A / 692A
页数：1
相关论文
共 50 条
  • [31] History of chronic comorbidity and risk of chemotherapy-induced febrile neutropenia in patients with non-Hodgkin lymphoma not receiving granulocyte colony-stimulating factor prophylaxis
    Chao, Chun
    Rodriguez, Roberto
    Page, John H.
    Yang, Su-Jau
    Huynh, Julie
    Chia, Victoria M.
    LEUKEMIA & LYMPHOMA, 2015, 56 (01) : 72 - 79
  • [32] A prospective, randomized clinical trial of emergency treatment of chemotherapy-induced neutropenia and febrile neutropenia by pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF)
    Huang, Xiaofeng
    Li, Shuo
    Shi, Wenjie
    Wang, Ye
    Wan, Xinyu
    He, Jinzhi
    Xu, Yinggang
    Zhang, Weiwei
    Shi, Xiaoqing
    Chen, Rui
    Xu, Lu
    Zha, Xiaoming
    Wang, Jue
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2023, 89 (01) : 372 - 379
  • [33] EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours
    Aapro, M. S.
    Cameron, D. A.
    Pettengell, R.
    Bohlius, J.
    Crawford, J.
    Ellis, M.
    Kearney, N.
    Lyman, G. H.
    Tjan-Heijnen, V. C.
    Walewski, J.
    Weber, D. C.
    Zielinski, C.
    EUROPEAN JOURNAL OF CANCER, 2006, 42 (15) : 2433 - 2453
  • [34] Optimal use of granulocyte-colony-stimulating factor in patients with cancer who are at risk for chemotherapy-induced neutropenia
    Cappozzo, C
    ONCOLOGY NURSING FORUM, 2004, 31 (03) : 569 - 574
  • [35] Incidence of chemotherapy-induced neutropenia and current practice of prophylaxis with granulocyte colony-stimulating factors in cancer patients in Spain: a prospective, observational study
    Jolis, L.
    Carabantes, F.
    Pernas, S.
    Cantos, B.
    Lopez, A.
    Torres, P.
    Funes, C.
    Caballero, D.
    Benedit, P.
    Salar, A.
    EUROPEAN JOURNAL OF CANCER CARE, 2013, 22 (04) : 513 - 521
  • [36] Defining the impact of the use of granulocyte colony stimulating factors on the incidence of chemotherapy-induced neutropenia in patients with gynecologic malignancies
    Julius, Justin M.
    Hammerstrom, Aimee
    Wei, Caimiao
    Rajesh, Raeshmma
    Bodurka, Diane C.
    Kurian, Shiney
    Smith, Judith A.
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2017, 23 (02) : 121 - 127
  • [37] INCIDENCE OF CHEMOTHERAPY-INDUCED NEUTROPENIA IN LYMPHOMA PATIENTS AND USE OF PROPHYLAXIS WITH GRANULOCYTE COLONY-STIMULATING FACTORS IN CLINICAL PRACTICE
    Salar, A.
    Lopez, A.
    Torres, J. Pio
    Lopez, M. D.
    Caballero, M. D.
    Prieto, E.
    Battle, M.
    Giraldo, P.
    Blasco, A.
    Benedit, P.
    Garrido, T.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 521 - 521
  • [38] Study Inclusion Criteria and Presentation of Results in a Meta-Analysis of Granulocyte Colony-Stimulating Factor for Prevention of Febrile Neutropenia Reply
    Kuderer, Nicole M.
    Dale, David C.
    Crawford, Jeffrey
    Lyman, Gary H.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (36) : E764 - E764
  • [39] Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related febrile neutropenia
    Vellenga, E
    UylDeGroot, CA
    deWit, R
    Keizer, HJ
    Lowenberg, B
    tenHaaft, MA
    deWitte, TJM
    Verhagen, CAH
    Stoter, GJ
    Rutten, FFH
    Mulder, NH
    Smid, WM
    deVries, EGE
    JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (02) : 619 - 627
  • [40] Febrile neutropenia (FN) and pegfilgrastim prophylaxis in breast cancer and non-Hodgkin’s lymphoma patients receiving high (> 20%) FN-risk chemotherapy: results from a prospective observational study
    Jean Paul Salmon
    Martin Smakal
    Charisios Karanikiotis
    Marek Z. Wojtukiewicz
    Yohann Omnes
    Lucy DeCosta
    Sally Wetten
    James O’Kelly
    Supportive Care in Cancer, 2019, 27 : 1449 - 1457
12345